Last updated: May 18, 2016
|CMS Measure ID:||CMS140v3|
Percentage of female patients aged 18 years and older with Stage IC through IIIC, ER or PR positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period
|Initial Patient Population:||
All female patients aged 18 years and older with a diagnosis of breast cancer
Equals Initial Patient Population with stage IC through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer
Patients who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period
|Measure Steward:||American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)|
|National Quality Strategy Domain:||Effective Clinical Care|
|Next Version:||Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer|
Higher score indicates better quality
For the eCQM version of this measure, the initial patient population for this measure has been limited to patients with a first recorded breast cancer diagnosis within the past 5 years, as opposed to accounting for that patient population through the use of an exception (as is the case for claims implementation). The numerator captures patients who are prescribed adjuvant tamoxifen or AI, or received adjuvant tamoxifen or AI during the 12 month period. Date of breast cancer diagnosis is defined as date of pathologic diagnosis.
The requirement of Count >=2 of Encounter, Performed is to establish that the eligible professional has an existing relationship with the patient.